PMID- 32410861
OWN - NLM
STAT- MEDLINE
DCOM- 20210709
LR  - 20210709
IS  - 1466-1861 (Electronic)
IS  - 0962-9351 (Print)
IS  - 0962-9351 (Linking)
VI  - 2020
DP  - 2020
TI  - Advanced Glycated apoA-IV Loses Its Ability to Prevent the LPS-Induced Reduction 
      in Cholesterol Efflux-Related Gene Expression in Macrophages.
PG  - 6515401
LID - 10.1155/2020/6515401 [doi]
LID - 6515401
AB  - We addressed how advanced glycation (AGE) affects the ability of apoA-IV to 
      impair inflammation and restore the expression of genes involved in cholesterol 
      efflux in lipopolysaccharide- (LPS-) treated macrophages. Recombinant human 
      apoA-IV was nonenzymatically glycated by incubation with glycolaldehyde (GAD), 
      incubated with cholesterol-loaded bone marrow-derived macrophages (BMDMs), and 
      then stimulated with LPS prior to measurement of proinflammatory cytokines by 
      ELISA. Genes involved in cholesterol efflux were quantified by RT-qPCR, and 
      cholesterol efflux was measured by liquid scintillation counting. 
      Carboxymethyllysine (CML) and pyrraline (PYR) levels, determined by Liquid 
      Chromatography-Mass Spectrometry (LC-MS/MS), were greater in AGE-modified apoA-IV 
      (AGE-apoA-IV) compared to unmodified-apoA-IV. AGE-apoA-IV inhibited expression of 
      interleukin 6 (Il6), TNF-alpha (Tnf), IL-1 beta (Il1b), toll-like receptor 4 
      (Tlr4), tumor necrosis factor receptor-associated factor 6 (Traf6), Janus kinase 
      2/signal transducer and activator of transcription 3 (Jak2/Stat3), nuclear factor 
      kappa B (Nfkb), and AGE receptor 1 (Ddost) as well as IL-6 and TNF-alpha 
      secretion. AGE-apoA-IV alone did not change cholesterol efflux or ABCA-1 levels 
      but was unable to restore the LPS-induced reduction in expression of Abca1 and 
      Abcg1. AGE-apoA-IV inhibited inflammation but lost its ability to counteract the 
      LPS-induced changes in expression of genes involved in macrophage cholesterol 
      efflux that may contribute to atherosclerosis.
CI  - Copyright (c) 2020 Ligia Shimabukuro Okuda et al.
FAU - Shimabukuro Okuda, Ligia
AU  - Shimabukuro Okuda L
AUID- ORCID: 0000-0003-0356-1543
AD  - Laboratorio de Lipides (LIM 10), Hospital das Clinicas (HCFMUSP), Faculdade de 
      Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.
FAU - Tallada Iborra, Rodrigo
AU  - Tallada Iborra R
AD  - Laboratorio de Lipides (LIM 10), Hospital das Clinicas (HCFMUSP), Faculdade de 
      Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.
AD  - Universidade Sao Judas Tadeu, Sao Paulo, Brazil.
FAU - Ramos Pinto, Paula
AU  - Ramos Pinto P
AD  - Laboratorio de Lipides (LIM 10), Hospital das Clinicas (HCFMUSP), Faculdade de 
      Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.
FAU - Fabres Machado, Ubiratan
AU  - Fabres Machado U
AUID- ORCID: 0000-0002-8237-2435
AD  - Department of Physiology and Biophysics, Institute of Biomedical Sciences, 
      University of Sao Paulo, Sao Paulo, Brazil.
FAU - Correa-Giannella, Maria Lucia
AU  - Correa-Giannella ML
AD  - Laboratorio de Carboidratos e Radioimunoensaio (LIM 18), Hospital das Clinicas 
      (HCFMUSP), Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.
AD  - Programa de Pos-Graduacao em Medicina, Universidade Nove de Julho, Sao Paulo, 
      Brazil.
FAU - Pickford, Russell
AU  - Pickford R
AD  - Bioanalytical Mass Spectrometry Facility, University of New South Wales, Sydney, 
      Australia.
FAU - Woods, Tom
AU  - Woods T
AD  - School of Chemical Sciences, University of Auckland, Auckland, New Zealand.
FAU - Brimble, Margaret Anne
AU  - Brimble MA
AD  - School of Chemical Sciences, University of Auckland, Auckland, New Zealand.
FAU - Rye, Kerry-Anne
AU  - Rye KA
AD  - Lipid Research Group, School of Medical Sciences, University of New South Wales, 
      Sydney, Australia.
FAU - Passarelli, Marisa
AU  - Passarelli M
AUID- ORCID: 0000-0002-9249-4698
AD  - Laboratorio de Lipides (LIM 10), Hospital das Clinicas (HCFMUSP), Faculdade de 
      Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.
AD  - Programa de Pos-Graduacao em Medicina, Universidade Nove de Julho, Sao Paulo, 
      Brazil.
LA  - eng
PT  - Journal Article
DEP - 20200114
PL  - United States
TA  - Mediators Inflamm
JT  - Mediators of inflammation
JID - 9209001
RN  - 0 (Apolipoproteins A)
RN  - 0 (Glycation End Products, Advanced)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Recombinant Proteins)
RN  - 0 (apolipoprotein A-IV)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - GO1N1ZPR3B (Acetaldehyde)
RN  - W0A0XPU08U (glycolaldehyde)
SB  - IM
MH  - Acetaldehyde/analogs & derivatives/chemistry
MH  - Animals
MH  - Apolipoproteins A/chemistry/*metabolism
MH  - Bone Marrow Cells/cytology
MH  - Cholesterol/*metabolism
MH  - Chromatography, Liquid
MH  - Gene Expression Profiling
MH  - *Glycation End Products, Advanced
MH  - Humans
MH  - Inflammation
MH  - Lipopolysaccharides/*chemistry
MH  - Macrophages/*metabolism
MH  - Mass Spectrometry
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Oxidative Stress
MH  - Recombinant Proteins/chemistry
PMC - PMC7201780
COIS- The authors declare that there is no conflict of interest regarding the 
      publication of this paper.
EDAT- 2020/05/16 06:00
MHDA- 2021/07/10 06:00
PMCR- 2020/01/14
CRDT- 2020/05/16 06:00
PHST- 2019/10/18 00:00 [received]
PHST- 2019/12/06 00:00 [revised]
PHST- 2019/12/21 00:00 [accepted]
PHST- 2020/05/16 06:00 [entrez]
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2021/07/10 06:00 [medline]
PHST- 2020/01/14 00:00 [pmc-release]
AID - 10.1155/2020/6515401 [doi]
PST - epublish
SO  - Mediators Inflamm. 2020 Jan 14;2020:6515401. doi: 10.1155/2020/6515401. 
      eCollection 2020.